Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;20(6):554-62.
doi: 10.4103/1735-1995.165956.

Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study

Mohammad Saadatnia  1 , Mansour Salehi  2 , Ahmad Movahedian  3 , Seyed Ziaeddin Samsam Shariat  3 , Mehri Salari  1 , Marzieh Tajmirriahi  1 , Elham Asadimobarakeh  1 , Rasoul Salehi  2 , Gilda Amini  2 , Homa Ebrahimi  4 , Ehsan Kheradmand  1
Affiliations

Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study

Mohammad Saadatnia et al. J Res Med Sci. 2015 Jun.

Abstract

Background: Factor V G1691A (FV Leiden), FII GA20210, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are the most common genetic risk factors for thromboembolism in the Western countries. However, there is rare data in Iran about cerebral venous and sinus thrombosis (CVST) patients. The aim of this study was to evaluate the frequency of common genetic thrombophilic factors in CVST patients.

Materials and methods: Forty consequently CVST patients from two University Hospital in Isfahan University of Medical Sciences aged more than 15 years from January 2009 to January 2011 were recruited. In parallel, 51 healthy subjects with the same age and race from similar population selected as controls. FV Leiden, FII GA20210, MTHFR C677T, and FV Cambridge gene mutations by polymerase chain reaction technique were evaluated in case and control groups.

Results: FV Leiden, FII GA20210, and FV Cambridge gene mutations had very low prevalence in both case (5%, 2%, 0%) and control (2.5%, 0%, 0%) and were not found any significant difference between groups. MTHFR C677T mutations was in 22 (55%) of patients in case group and 18 (35.5%) of control group (P = 0.09).

Conclusion: This study showed that the prevalence of FV Leiden, FII GA20210, and FV Cambridge were low. Laboratory investigations of these mutations as a routine test for all patients with CVST may not be cost benefit.

Keywords: Cerebral venous and sinus thrombosis; factor II GA20210; factor V Cambridge; factor V Leiden; methylenetetrahydrofolate reductase.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kniffin WD, Baron JA, Barret J, Birkmeyer JD, Anderson FA., Jr The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994154861-866.866. - PubMed
    1. Koopman K, Uyttenboogaart M, Hendriks HG, Luijckx GJ, Cramwinckel IR, Vroomen PC, et al. Thromboelastography in patients with cerebral venous thrombosis. Thromb Res. 2009;124:185–8. - PubMed
    1. Aaron S, Alexander M, Maya T, Mathew V, Goel M, Nair SC, et al. Underlying prothrombotic states in pregnancy associated cerebral venous thrombosis. Neurol India. 2010;58:555–9. - PubMed
    1. Kenet G, Kirkham F, Niederstadt T, Heinecke A, Saunders D, Stoll M, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: A multicentre cohort study. Lancet Neurol. 2007;6:595–603. - PMC - PubMed
    1. Bousser MG, Ferro JM. Cerebral venous thrombosis: An update. Lancet Neurol. 2007;6:162–70. - PubMed